According to the report, the Global Antibody Drug Conjugates Market Size is valued at USD 11.8 Billion in 2020 and estimated to be growing at a CAGR of 24.74%, to reach USD 35.6 Billion by 2025.
MARKET OVERVIEW
Antidrug body conjugates are the drugs used to treat cancer patients. These are used to kill away the cancer cells present in the body. The U.S. FDA has accepted some of the Antibody-drug conjugates, and many more are on clinical trials, and this is one of the significant factors that drive the market. Especially the North American region is the most demanding market of antibody-drug conjugate. Cell Mosaic has invented a new Antibody Mertansine conjugation kit with SMCC and DM1. This kit offers an easy and straightforward way of labeling the lgG with DM1.
Drivers
Factors that are responsible for the Antibody-drug conjugates market growth are lifestyle changes, growing occurrences of cancer, and also increasing advanced technology. The increase of theoretical researches about the drug conjugates market is driving forward.
Pharmaceutical companies and biotechnology companies are joining together to form one for the development of new novel drug discoveries, and this is propelling the market growth. The growing research on cancer-related diseases is also fueling the market.
Restrains
The cost related to the antibody-drug conjugates is so high that people can’t afford to buy, and strict rules and regulations to be followed during the time of approval of products are hindering the market growth. Shortage of funds also restrains the market growth.
COVID-19 IMPACT ON ANTIBODY DRUG CONJUGATES MARKET
The COVID 19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Global Economy had negatively affected during the pandemic. The Antibody Drug Conjugates Market had gone through some rough times during the pandemic. Due to supply chain constraints, the companies are facing short-term operational challenges. Because of the pandemic, the projects in China, the US, Germany, and South Korea are delayed, which affected the growth of the Antibody Drug Conjugates Market. But the market is getting into profits post-COVID 19 with the help of market players.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 – 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 - 2025 |
|
Segments Covered |
By Pipeline, Technology, End-User, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals. |
This market research report on Global Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2025.
Antibody Drug Conjugates Market - By Pipeline
Antibody Drug Conjugates Market - By Technology
Antibody Drug Conjugates Market - By End User
REGIONAL ANALYSIS
Geographically, North America leads the Global Antibody Drug Conjugates Market. The Size of the North America Antibody Drug Conjugates Market is valued at USD 3.6 billion in 2020. By 2025, the market is estimated to reach USD 10.26 billion at a CAGR of 23.32% during the forecast period. The rise in the awareness among the patients in early diagnosis is driving the market. The increase in usage of antibody-drug conjugates (ADC) and the rise in the prevalence of cancer are boosting the market. The United States is dominating the North American Antibody Drug Conjugates Market due to the presence of high cancer patients in this region. Moreover, the increased investments by the companies in the pipeline analysis and technological advancements are boosting the market. Canada is expected to grow with a high CAGR in the coming years due to increased government funding in the research and large pharmaceutical companies in this region.
The European antibody-drug conjugate market is the second-largest market. The market size is valued at USD 2.47 billion in 2020, and by 2025, the market is estimated to reach USD 7.56 billion at a CAGR of 25.12% during the forecast period. The increase in cancer & bone marrow surgeries is driving the European antibody-drug conjugate market. The rise in awareness programs by the government and the presence of significant market players are fueling the market. Germany leads the global market, followed by France and U.K. The presence of favorable reimbursement policies and the rise in government and private to develop advanced technology in these regions are propelling the European antibody-drug conjugate market.
The Asia-Pacific region is the fastest-growing region with a high CAGR due to the rise in prevalence of cancer, and expanding health care infrastructure is driving the market. The rising awareness among consumers and growing government initiatives are propelling the Asia Pacific Antibody Drug Conjugates Market.
Latin America and Middle East & Africa are expected to have significant growth opportunities in the coming years.
Recent Market Developments in the Antibody Drug Conjugates Industry
List of Companies Operating the Global Antibody Drug Conjugate Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, Synthon Biopharmaceuticals
Appendix
Related Reports
